Total Payments
$9,793
2024 Payments
$4,596
Companies
54
Transactions
341
Medicare Patients
4,679
Medicare Billing
$372,491
Payment Breakdown by Category
Food & Beverage$6,831 (69.8%)
Travel$1,654 (16.9%)
Research$1,115 (11.4%)
Education$193.93 (2.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,831 | 329 | 69.8% |
| Travel and Lodging | $1,654 | 4 | 16.9% |
| Unspecified | $1,115 | 3 | 11.4% |
| Education | $193.93 | 5 | 2.0% |
Payments by Type
General
$8,678
338 transactions
Research
$1,115
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $2,782 | 8 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $721.12 | 17 | $0 (2024) |
| PFIZER INC. | $456.38 | 18 | $0 (2024) |
| Genentech USA, Inc. | $436.25 | 22 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $414.26 | 23 | $0 (2024) |
| Incyte Corporation | $338.47 | 14 | $0 (2024) |
| ABBVIE INC. | $334.20 | 16 | $0 (2024) |
| Celgene Corporation | $305.38 | 23 | $0 (2024) |
| Janssen Biotech, Inc. | $257.10 | 14 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $253.76 | 13 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,596 | 98 | Regeneron Pharmaceuticals, Inc. ($2,782) |
| 2023 | $2,099 | 110 | Genentech USA, Inc. ($205.56) |
| 2022 | $1,700 | 93 | Genentech USA, Inc. ($175.76) |
| 2021 | $48.67 | 3 | Novartis Pharmaceuticals Corporation ($36.75) |
| 2020 | $26.67 | 2 | Alexion Pharmaceuticals, Inc. ($15.65) |
| 2019 | $349.92 | 12 | Foundation Medicine, Inc. ($112.08) |
| 2018 | $693.35 | 15 | AstraZeneca Pharmaceuticals LP ($377.25) |
| 2017 | $279.23 | 8 | PFIZER INC. ($145.14) |
All Payment Transactions
341 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $15.30 | General |
| Category: Oncology | ||||||
| 12/13/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $25.31 | General |
| Category: Oncology | ||||||
| 12/12/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $23.55 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $8.41 | General |
| Category: Oncology | ||||||
| 12/05/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $24.93 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Myriad Genetic Laboratories, Inc. | MYRISK (Device) | Food and Beverage | In-kind items and services | $22.62 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $12.59 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | JAZZ PHARMACEUTICALS INC. | RYLAZE (Drug) | Food and Beverage | In-kind items and services | $24.01 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/14/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $22.46 | General |
| Category: Oncology | ||||||
| 11/12/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $13.22 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $34.79 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $17.56 | General |
| Category: Oncology | ||||||
| 10/30/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.22 | General |
| 10/30/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $16.68 | General |
| Category: Oncology | ||||||
| 10/29/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $16.78 | General |
| Category: Immunology | ||||||
| 10/25/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $20.78 | General |
| Category: Oncology | ||||||
| 10/23/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $18.01 | General |
| Category: ONCOLOGY | ||||||
| 10/22/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $20.11 | General |
| Category: Oncology | ||||||
| 10/11/2024 | Genentech USA, Inc. | Kadcyla (Biological), Perjeta, Phesgo | Food and Beverage | In-kind items and services | $14.49 | General |
| Category: BioOncology | ||||||
| 10/08/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $15.33 | General |
| Category: ONCOLOGY | ||||||
| 10/01/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $24.41 | General |
| Category: Oncology | ||||||
| 09/27/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $11.98 | General |
| Category: Oncology | ||||||
| 09/26/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $25.88 | General |
| Category: Oncology | ||||||
| 09/20/2024 | Regeneron Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $701.22 | General |
| 09/20/2024 | Regeneron Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $701.22 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20X ANTI-CD3 BISPECIFIC ANTIBODY, COMBINED WITH CHEMOTHERAPY VERSUS RITUXIMAB COMBINED WITH CHEMOTHERAPY IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-2) | Regeneron Pharmaceuticals, Inc. | $776.66 | 2 |
| AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | Regeneron Pharmaceuticals, Inc. | $337.90 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 41 | 1,679 | 25,387 | $382,956 | $149,956 |
| 2022 | 41 | 1,588 | 16,789 | $351,164 | $134,540 |
| 2021 | 25 | 918 | 1,556 | $138,140 | $55,456 |
| 2020 | 4 | 494 | 707 | $99,285 | $32,538 |
Total Patients
4,679
Total Services
44,439
Medicare Billing
$372,491
Procedure Codes
114
All Medicare Procedures & Services
114 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 172 | 355 | $67,005 | $31,571 | 47.1% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 16 | 20,250 | $35,438 | $17,668 | 49.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 65 | 184 | $33,120 | $16,774 | 50.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 82 | 86 | $26,101 | $11,227 | 43.0% |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | Office | 2023 | 24 | 676 | $55,432 | $11,049 | 19.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 27 | 63 | $18,396 | $5,816 | 31.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 162 | 713 | $10,861 | $5,795 | 53.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 53 | 53 | $15,105 | $5,317 | 35.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 161 | 683 | $18,052 | $5,198 | 28.8% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 17 | 68 | $4,760 | $5,076 | 106.6% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 14 | 85 | $10,455 | $4,468 | 42.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 25 | 34 | $8,985 | $4,193 | 46.7% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 109 | 338 | $11,965 | $3,469 | 29.0% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2023 | 19 | 19 | $4,850 | $2,269 | 46.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 26 | 47 | $7,097 | $2,157 | 30.4% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 58 | 119 | $5,516 | $1,590 | 28.8% |
| 83521 | Measurement of immunoglobulin light chains | Office | 2023 | 23 | 86 | $3,713 | $1,456 | 39.2% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 17 | 17 | $4,012 | $1,440 | 35.9% |
| 88184 | Flow cytometry technique for dna or cell analysis, first marker | Office | 2023 | 24 | 29 | $4,524 | $1,363 | 30.1% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2023 | 23 | 130 | $4,112 | $1,185 | 28.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 15 | 19 | $2,394 | $1,158 | 48.4% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 20 | 94 | $3,234 | $1,050 | 32.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 38 | 106 | $4,028 | $1,049 | 26.1% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 16 | 16 | $2,081 | $1,026 | 49.3% |
| 84466 | Transferrin (iron binding protein) level | Office | 2023 | 47 | 73 | $2,897 | $912.50 | 31.5% |
About Dr. Colin Hardin, M.D
Dr. Colin Hardin, M.D is a Hematology & Oncology healthcare provider based in Grand Rapids, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/19/2011. The National Provider Identifier (NPI) number assigned to this provider is 1639459860.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Colin Hardin, M.D has received a total of $9,793 in payments from pharmaceutical and medical device companies, with $4,596 received in 2024. These payments were reported across 341 transactions from 54 companies. The most common payment nature is "Food and Beverage" ($6,831).
As a Medicare-enrolled provider, Hardin has provided services to 4,679 Medicare beneficiaries, totaling 44,439 services with total Medicare billing of $372,491. Data is available for 4 years (2020–2023), covering 114 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Grand Rapids, MI
- Active Since 08/19/2011
- Last Updated 04/14/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1639459860
Products in Payments
- TAGRISSO (Drug) $329.49
- IMBRUVICA (Drug) $324.99
- VENCLEXTA (Drug) $247.83
- JAKAFI (Drug) $244.84
- KEYTRUDA (Biological) $208.89
- REBLOZYL (Biological) $162.59
- IBRANCE (Drug) $152.43
- ENHERTU (Biological) $135.29
- KISQALI (Drug) $125.52
- XALKORI (Drug) $125.00
- FOUNDATIONONE (Device) $124.06
- Venclexta (Biological) $124.04
- VENCLEXTA (Biological) $120.41
- ONUREG (Drug) $119.53
- OJJAARA (Drug) $117.88
- FASENRA (Drug) $113.40
- BRUKINSA (Drug) $110.47
- SARCLISA (Biological) $110.36
- Cabometyx (Drug) $108.31
- OPDIVO (Biological) $99.14
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Grand Rapids
Sreenivasa Chandana, Md, MD
Hematology & Oncology — Payments: $324,757
Hematology & Oncology $324,757
Anas Al-Janadi, M.d, M.D
Hematology & Oncology — Payments: $190,436
Hematology & Oncology $190,436
Dr. Nehal Lakhani, M.d, M.D
Hematology & Oncology — Payments: $49,125
Hematology & Oncology $49,125
Dr. Eric Santos, M.d, M.D
Hematology & Oncology — Payments: $13,987
Hematology & Oncology $13,987
Dr. Amy Vander Woude, M.d, M.D
Hematology & Oncology — Payments: $9,795
Hematology & Oncology $9,795
Dr. Erin Pettijohn, M.d, M.D
Hematology & Oncology — Payments: $9,227
Hematology & Oncology $9,227